Docket No.

268519US0PCT



IN THE UNITED STATES PA

IN RE APPLICATION OF:

Masaomi IYO, et al.

· SERIAL NO:

10/528,814~

GAU:

FILED: (FOR:

1.44

March 23, 2005

EXAMINER:

DIAGNOSTIC AND EXAMINATION METHOD FOR EATING DISORDER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

■ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

U.O. DEDARTMENT OF COMMERCE				ATTY DOCKET NO.		SERIAL NO. 10/528,814			
orm PTO 1449 U.S. DEPARTMENT OF COMMERCE Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			268519US0PCT						
				APPLICANT					
LIST OF I	REFERI	ENCES CITED BY APPL	ICANT	Masaomi IYO, et al.					
				FILING DATE		GROUP 1649			
r,				March 23, 2005					
				U.S. PATENT DOCUMENTS					
EXAMINER		DOCUMENT		NAME	CLASS	SUB	FILIN	G DATE ROPRIATE	
INITIAL		NUMBER	DATE	IVANIC	-	CLASS	IF APPI	TOPRIATE	
	AA				<u> </u>	<u> </u>	-		
	AB				<u> </u>	<u> </u>			
	AC					<u> </u>			
	AD				ļ	ļ			
	AE				<u> </u>				
	AF				ļ	ļ	<u> </u>		
	AG				ļ	ļ			
	AH					ļ		·	
	Al					ļ			
	AJ					<u> </u>			
	AK					<u> </u>			
	AL						ļ		
	AM						<u> </u>		
	AN				<u> </u>		<u> </u>		
	٠.		F	OREIGN PATENT DOCUMENTS					
							TRANSLA	TION	
		DOCUMENT NUMBER	DATE	COUNTRY		YE		NO	
	-			JP (equivalent of WO 94/06455 - Eng	High _{ess}			NO	
/ 1 1 1 1 1 1 ./	AO	8-501313	02/13/96	abstractionly)		- 		NO	
/R.H./	AP	94/23736	10/27/94	wo					
	AQ					+			
	AR								
	AS								
	AT		l						
		OTHER RE	FERENCES	6 (Including Author, Title, Date, Pertine	ent Pages,	etc.)			
/R.H./	AU	restrictive type", Molec	ular Psychia	rain-derived neurotrophic factor (BDNF) stry, vol. 8, pages 745-751					
000000000000000000000000000000000000000	AV	RIBASES, M. et al. "Va nervosa restrictive type	et al. "Val66Met in the Brain Derived Neurotrophic Factor (BDNF) Precursor is associated with anorexia tive type", American Journal of Medical Genetics, vol. 114, no. 7, page 739, O71						
000000000000000000000000000000000000000	AW	NAKAZATO, Michiko et al. "Decreased Levels of Serum Brain-Derived Neurotrophic Factor in Female Patients with Eatin Disorders", Biol. Psychiatry, vol. 54, pages 485-490							
2000000	AX	69-84		ctive Serotonin-Reuptake Inhibitors: An Update", Harv. Rev. Psychiatry, vol. 7, no. 2, pag					
30000000000000000000000000000000000000	AY	Bulimia Nervosa", Bio	erotonin Ne I. Psychiatry	uronal Function and Selective Serotonin Reuptake Inhibitor Treatment in Anorexia and , vol. 44, pages 825-838					
V	AZ	develop aggrectivene	ee and hyne	. "Brain-derived neurotrophic factor-deficient mice s and hyperphagia in conjunction with brain ies", PNAS, vol. 96, no. 26, pages 15239-15244					
Examiner		/Robert Ha	ves/		Date	Date Considered 03/24/2008			
AFT	: Initial if	f reference is considered	whether or	not citation is in conformance with MPEF	9 609; Drav	w line throu	igh citation i	f not in	
conforman	ce and	not considered. Include o	opy or mis t	orm with next communication to applican					

U.S. PCT Application Serial No.: 10/528,814 Docket No.: <u>268519US0PCT</u>

STATEMENT OF RELEVANCY

1) References <u>AO, AP, AU-AW</u> have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
2) References have been cited in the corresponding Search Report A copy of these references is being submitted herewith.
3) References <u>AX-AZ</u> are discussed in the specification. A copy of these references is being submitted here with.
4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.